AI assistant
Sending…
DAVITA INC. — Director's Dealing 2016
May 12, 2016
30643_dirs_2016-05-11_503f857b-8967-4ac9-831f-498196553fda.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: DAVITA HEALTHCARE PARTNERS INC. (DVA)
CIK: 0000927066
Period of Report: 2016-05-10
Reporting Person: Kogod Dennis (Pres, HCP & CEO, DVA Int.)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2016-05-10 | Common Stock | M | 56250 | $55.34 | Acquired | 92716 | Direct |
| 2016-05-10 | Common Stock | F | 40938 | $76.04 | Disposed | 51778 | Direct |
| 2016-05-10 | Common Stock | S | 15312 | $76.25 | Disposed | 36466 | Direct |
| 2016-05-10 | Common Stock | M | 110000 | $58.94 | Acquired | 146466 | Direct |
| 2016-05-10 | Common Stock | F | 85264 | $76.04 | Disposed | 61202 | Direct |
| 2016-05-10 | Common Stock | S | 24736 | $76.25 | Disposed | 36466 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2016-05-10 | Stock Appreciation Rights | $55.34 | M | 56250 | Disposed | 2017-12-18 | Common Stock (56250) | Direct |
| 2016-05-10 | Stock Appreciation Rights | $58.94 | M | 110000 | Disposed | 2018-03-19 | Common Stock (110000) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 84350 | Indirect |
Footnotes
F1: The Stock Appreciation Rights were granted on 12/18/2012. 50% vested on 4/1/2015 and the remaining 50% vested on 4/1/2016.
F2: The Stock Appreciation Rights were granted on 3/19/2013. 50% vested on 3/19/2016 and the remaining 50% will vest on 3/19/2017.
More from DAVITA INC.
Interim / Quarterly Report
2026
May 5
Annual Report
2026
Apr 22
Proxy Solicitation & Information Statement
2026
Apr 22
Annual Report
2026
Feb 11
Director's Dealing
2026
Feb 10
Director's Dealing
2026
Feb 10
Earnings Release
2026
Feb 2
Director's Dealing
2026
Feb 2
Director's Dealing
2025
Dec 5
Capital/Financing Update
2025
Nov 25